343
Views
28
CrossRef citations to date
0
Altmetric
Technology Evaluation

A structural feature-based computational approach for toxicology predictions

, , &
Pages 505-518 | Published online: 14 Jan 2010

Bibliography

  • FDA. Challenge and opportunity on the critical path to new medical products. Available from URL: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm 10 August 2009. 2004 [cited 2009; Available from: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
  • Valerio LG Jr, Arvidson KB, Chanderbhan RF, Contrera JF. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling. Toxicol Appl Pharmacol 2007;222(1):1-16
  • Kruhlak NL, Choi SS, Contrera JF, Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol Mech Methods 2008;18(2):217-27
  • Bailey AB, Chanderbhan R, Collazo-Braier N, The use of structure-activity relationship analysis in the food contact notification program. Regul Toxicol Pharmacol 2005;42(2):225-35
  • Mayer J, Cheeseman MA, Twaroski ML. Structure-activity relationship analysis tools: validation and applicability in predicting carcinogens. Regul Toxicol Pharmacol 2008;50(1):50-8
  • Tong W, Welsh WJ, Shi L, Structure-activity relationship approaches and applications. Environ Toxicol Chem 2003;22(8):1680-95
  • Beger RD, Harris S, Xie Q. Models of steroid binding based on the minimum deviation of structurally assigned 13C NMR spectra analysis (MiDSASA). J Chem Inf Comput Sci 2004;44(4):1489-96
  • Yu H, Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discov Today 2003;8(18):852-61
  • Segall MD, Beresford AP, Gola JMR, Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery. Expert Opin Drug Metab Toxicol 2006;2(2):325-37
  • Dearden JC. In silico prediction of ADMET properties: how far have we come? Expert Opin Drug Metab Toxicol 2007;3(5):635-9
  • Yang C, Cross K, Myatt GJ, Building predictive models for protein tyrosine phosphatase 1B inhibitors based on discriminating structural features by reassembling medicinal chemistry building blocks. J Med Chem 2004;47(24):5984-94
  • Matthews EJ, Kruhlak NL, Benz RD, Combined use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows software to achieve high-performance, high-confidence, mode of action-based predictions of chemical carcinogenesis in rodents. Toxicol Mech Methods 2008;18(2):189-206
  • Ursem CJ, Kruhlak NL, Contrera JF, Identification of structure activity relationships for adverse effects of pharmaceuticals in humans: A. Use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009;54(1):1-22
  • Roberts G, Myatt GJ, Johnson WP, LeadScope: software for exploring large sets of screening data. J Chem Inf Comput Sci 2000;40(6):1302-14
  • Cross KP, Myatt G, Yang C, Finding discriminating structural features by reassembling common building blocks. J Med Chem 2003;46(22):4770-5
  • Geladi P, Kowalski BR. Partial least-squares regression: a tutorial. Anal Chim Acta 1986;185:1-17
  • Nguyen DV, Rocke DM. Tumor classification by partial least squares using microarray gene expression data. Bioinformatics 2002;18(1):39-50
  • Wold S. Chemometrics: mathematics and statistics in chemistry. Reidel, Dordrecht; 1984
  • Wold S. Food research and data analysis. Applied Science Publications, London; 1983
  • Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 1989;29(3):307-35
  • Contrera JF, Maclaughlin P, Hall LH, Kier LB. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr Drug Discov Technol 2005 2005;2(2):55-67
  • Matthews EJ, Contrera JF. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul Toxicol Pharmacol 1998;28(3):242-64
  • Valerio LG Jr, Arvidson KB, Busta E, Testing computational toxicology models with phytochemicals. Mol Nutr Food Res 2009. In press
  • Matthews EJ, Kruhlak NL, Benz RD, Contrera JF. A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database. Regul Toxicol Pharmacol 2007;47(2):115-35
  • Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. Regul Toxicol Pharmacol 2005;43(3):313-23
  • Matthews EJ, Kruhlak NL, Benz RD, Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009;54(1):43-65
  • Matthews EJ, Ursem CJ, Kruhlak NL, Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009;54(1):23-42

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.